Multiple Sclerosis and Related Disorders

Challenging clinical decisions in pregnancy planning with MS and NMOSD patients 1:56
Challenging clinical decisions in pregnancy planning with MS and NMOSD patients
Melinda Magyari • 28 Oct 2022
Comparison of unwrapped phase and QSM for paramagnetic rim lesion detection in MS 1:45
Comparison of unwrapped phase and QSM for paramagnetic rim lesion detection in MS
Cristina Granziera • 28 Oct 2022
The pathology of MS and MOGAD: similarities and differences 1:49
The pathology of MS and MOGAD: similarities and differences
Hans Lassmann • 27 Oct 2022
Current treatment guidelines: pregnancy in MS and NMOSD 1:26
Current treatment guidelines: pregnancy in MS and NMOSD
Melinda Magyari • 28 Oct 2022
Future research options in polypharmacy associated with multiple sclerosis 1:45
Future research options in polypharmacy associated with multiple sclerosis
Anibal Chertcoff • 28 Oct 2022
Pregnancy and infant outcomes in women with MS receiving ocrelizumab 1:33
Pregnancy and infant outcomes in women with MS receiving ocrelizumab
Celia Oreja-Guevara • 28 Oct 2022
Current challenges in MS neuroimaging 1:29
Current challenges in MS neuroimaging
Cristina Granziera • 28 Oct 2022
Spinal cord reserve: validation of SCaA-SCT in a prospective cohort of MS patients 2:35
Spinal cord reserve: validation of SCaA-SCT in a prospective cohort of MS patients
Jaume Sastre-Garriga • 28 Oct 2022
Implementing MS imaging biomarkers into everyday practice 1:23
Implementing MS imaging biomarkers into everyday practice
Cristina Granziera • 28 Oct 2022
The immune mechanisms behind neurodegeneration in progressive MS 2:55
The immune mechanisms behind neurodegeneration in progressive MS
Hans Lassmann • 27 Oct 2022
Limitations of MS treatment guidelines 1:10
Limitations of MS treatment guidelines
Eva Kubala Havrdová • 27 Oct 2022
Impacts of polypharmacy on MS patients’ outcomes 2:07
Impacts of polypharmacy on MS patients’ outcomes
Anibal Chertcoff • 28 Oct 2022
Challenges in MS management: individualized treatments 1:05
Challenges in MS management: individualized treatments
Eva Kubala Havrdová • 27 Oct 2022
Population-based study on polypharmacy and multiple sclerosis 6:12
Population-based study on polypharmacy and multiple sclerosis
Anibal Chertcoff • 28 Oct 2022
Deciding on a tailored treatment strategy for MS patients 1:46
Deciding on a tailored treatment strategy for MS patients
Eva Kubala Havrdová • 27 Oct 2022
Protective and pro-inflammatory lipid mediators in MS 1:22
Protective and pro-inflammatory lipid mediators in MS
Gijs Kooij • 27 Oct 2022
The content of VJNeurology is intended for healthcare professionals